Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04492722 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 613
- Enrollment target
NCT04492722 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 613 participants.
The verdict
NCT04492722, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 613 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.
Interventions
- DRUG Placebo
- DRUG Dapagliflozin 10 mg
- DRUG AZD5718
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 613 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2022-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04492722
The ClinicalTrials.gov registry entry for NCT04492722 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 613 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04492722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04492722 about?
NCT04492722 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease". The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.
What is the current status of trial NCT04492722?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 613 participants. The study started on 2020-10-01. Estimated completion is 2022-09-06.
What interventions are being tested in trial NCT04492722?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin 10 mg (DRUG), AZD5718 (DRUG).
Who is sponsoring clinical trial NCT04492722?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.